Viability of Breast Conservation Therapy Gives Patients ‘More of a Choice,’ Says Expert

Video

Judy C. Boughey, MD, of Mayo Clinic in Rochester, Minnesota indicated that breast conservation therapy, if it can be proven as a reasonable option for patients with multiple ipsilateral breast cancer, could offer patients more choice in treatment.

Demonstrating breast conservation surgery as a reasonable option for patients with multiple ipsilateral breast cancer may give women more of a choice in terms of treatment, according to Judy C. Boughey, MD.

During the 2022 San Antonio Breast Cancer Symposium (SABCS), CancerNetwork® spoke with Boughey, a surgical oncologist of the Division of Breast and Melanoma Surgical Oncology and the Department of Surgery at Mayo Clinic in Rochester, Minnesota, about the historical reasons why mastectomy is still used today and the potential impact of breast conservation therapy on local recurrence rates.

As such, Boughey and her colleagues aimed to assess the efficacy of breast conservation therapy as part of the phase 2 ACOSOG Z11102 (NCT01556243).

Transcript:

Women who have multiple ipsilateral breast cancer are often recommended for mastectomy. And this is based off the literature that historically showed a high rate of local recurrence in the breast; patients were treated with breast conservation if they had more than one foci of disease in the breast.

However, some more recent contemporary single institution studies have been reassuring and showing some lower local recurrence rates with the use of breast conserving surgery in patients with multiple ipsilateral breast cancer. We thought that this was an important question to ask for our patients in a prospective clinical trial.

We're seeing more and more patients who are being worked up for breast cancer and then being diagnosed with multiple foci of disease in the breast [due to] advances in screening, increased use of screening, and improvements in not only the screening modalities, but also diagnostic modalities, as well as the use of MRI.

With more use of MRI, you've got a higher likelihood of finding a second small foci elsewhere in the breast, [which] then at times commits the patient to require a mastectomy. If we could show that breast conservation surgery was a reasonable option for these women, then these women would have more of a choice.

Reference

Boughey JC, Rosenkranz KM, Ballman KV, et al. Impact of breast conservation therapy on local recurrence in patients with multiple ipsilateral breast cancer – results from ACOSOG Z11102 (Alliance). Presented at the 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022; San Antonio, TX; abstract GS4-01.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Stage IV lung cancer may be curable based on the success of the DREAM Program, according to thoracic surgeon, Ankit Bharat, MBBS,
Ankit Bharat, MBBS, a thoracic surgeon, discussed potential treatment emergent adverse effects or complications, as well as strategies for managing them.
The Jack & Sheryl Morris Cancer Center offers “state-of-the-art” surgical suites and advanced radiation technology, says Andrew M. Evens, DO, MBA, MSc.
Related Content